Lecithin
- Generic Name
- Lecithin
- Drug Type
- Small Molecule
- CAS Number
- 8002-43-5
- Background
A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
- Indication
用于脂肪肝、动脉粥样硬化等疾病的辅助治疗。
Study to Investigate the Absolute Bioavailability of Oral Sylibin
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Legalón SIL
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2016-07-11
- Target Recruit Count
- 8
- Registration Number
- NCT02633696
- Locations
- 🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 147
- Registration Number
- NCT02517385
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT02280629
- Locations
- 🇩🇪
Agaplesion Markus-Krankenhaus, Frankfurt a.M., Germany
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 468
- Registration Number
- NCT02142725
- Locations
- 🇩🇪
Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine, Frankfurt a.M., Germany
Phosphatidylcholine Supplementation in Infants
- Conditions
- SchizophreniaDiminished P50 Sensory Gating
- Interventions
- Drug: placebo
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT01905605
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
- Conditions
- Ulcerative ColitisLarge IntestineDiarrheaAbdominal Pain
- Interventions
- Drug: placebo
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Lipid Therapeutics GmbH
- Target Recruit Count
- 156
- Registration Number
- NCT01011322
- Locations
- 🇩🇪
University Clinics des Saarlandes, Homburg/Saar, Saarland, Germany
🇩🇪Universitaetsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
🇩🇪City Hospital Braunschweig, Braunschweig, Lower Saxony, Germany
A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal
- Conditions
- Obesity
- Interventions
- Drug: Saline
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT00851747
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Study to Evaluate the Effect of Injection Lypolysis (Lipodissolve) Treatments to Reduce Body Fat
- Conditions
- Abdominal Subcutaneous Fat
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- BodyAesthetic Research Center
- Target Recruit Count
- 20
- Registration Number
- NCT00757081
- Locations
- 🇺🇸
BodyAesthetic Research Center, Creve Coeur, Missouri, United States
Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 132
- Registration Number
- NCT00463619
- Locations
- 🇩🇪
University Heidelberg - Dep. Gastroenterology, Heidelberg, Germany
Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Heidelberg University
- Registration Number
- NCT00259571
- Locations
- 🇩🇪
Medical Hospital - University of Heidelberg, Heidelberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.